Skip to main content
Search

University of Milan

2 related articles

Subscribe to updates
  1. Research Square

    A Community-driven Hub for High-Quality Text2Cypher Benchmarks and Resources

    This work introduces Text2Cypher-Hub, a community platform for disseminating, discovering, and reusing Text2Cypher resources, and as its initial contribution releases three curated benchmarks---bio2C, twt2C, and fin2C---covering biomedical, social-media, and financial property graphs, together comprising 6,500 technically and semantically validated natural-language-to-Cypher pairs spanning five complexity categories, while describing the curation workflow and demonstrating suitability for supervised fine-tuning and retrieval-augmented generation pipelines.

    University of Milan
    Emanuele Cavalleri（First author）
    Text2Cypher-HubText2Cypherbio2C, twt2C, and fin2C benchmarks
  2. Current Opinion in Oncology

    Safety Management of Anti-TROP2 ADCs in Patients with Breast Cancer

    This review indicates that TROP2-directed antibody-drug conjugates (ADCs) are becoming increasingly integrated into breast cancer treatment across multiple disease settings, and that although sacituzumab govitecan and datopotamab deruxtecan share TROP2 targeting and topoisomerase I inhibition, their safety profiles differ—sacituzumab govitecan is mainly associated with neutropenia and diarrhoea, whereas datopotamab deruxtecan is characterized by stomatitis, ocular surface events and a low but clinically relevant risk of interstitial lung disease/pneumonitis—differences attributed to the integrated effects of payload, linker stability, drug-to-antibody ratio, tissue distribution and target-independent uptake, with corresponding agent-specific, proactive and increasingly individualized preve

    University of Milan
    Bianca Malagutti（First author）
    TROP2-directed antibody–drug conjugatesSacituzumab govitecanDatopotamab deruxtecan

You’re all caught up